HOME>Investor Relations

Investor Relations

Open Up the Future　医療の未来を切り開く

Top Interview
Talk about the "Medium-Term Management Plan 16-20"

President & Representative Director
Masayuki Mitsuka

Interviewer: Economic caster Yuka Tanimoto

Share Price Information

IR Calendar

2018
May 9
Announcement of FY2017 Financial Results
February 5
Announcement of FY2017 3rd Quater Financial Results
2017
November 1
Announcement of FY2017 2nd Quater Financial Results

IR Calendar list

What's New

  • RSS
  • About RSS

News Release List

2018
April 10 Release Update of Previous Disclosure ― Announcement of Filing a Request for Arbitration on the Licensing Agreement with Kolon Life SciencePDF
April 10 Release To ALS patients in the world, we hope to deliver Japan-originated ALS treatment―Health Canada accepts our filing for Edaravone to treat ALS and we established commercializing company in CanadaPDF
March 26 Release Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug DevelopmentPDF
March 6 Release Name Change of our Singapore SubsidiaryPDF
March 1 Release Mitsubishi Tanabe Pharma Group started marketing CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitus in TaiwanPDF
February 28 Release Valixa Tablet 450mg ―Public knowledge-based application for an additional pediatric indication for the prevention of CMV disease in organ transplant patients as well as application for an additional dosage form of dry syrupPDF
February 5 Topics IR Meeting for FY2017 3rd Quarter Business Results[Material][Audio]
February 5 Release Announcement of FY2017 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
January 23 Release Swissmedic accepts our filing for Edaravone to treat ALS ― To ALS patients in the world, we hope to deliver Japan-originated ALS treatmentPDF
January 16 Release Approval in China Received for Additional Novastan Indication for Acute Cerebral Infarction ― Reinforcing Our Pharmaceutical Development and Sales in China, the World's Second Largest Pharmaceutical MarketPDF
January 11 Release Launch of "KREMEZIN Tablets 500mg" (Additional Formulation), Drug for Chronic Renal Failure ― For Improving Patients' Usage Experience and Medication Adherence ―PDF
  • FTSE4Good
  • FTSE Blossom Japan
  • MSCI日本株女性活躍指数
  • MSCIジャパンESGセレクトリーダーズ指数
  • JPX-NIKKEI 400

Investor Relations

Share Price Information

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide